SCHEMBL5767206

SCHEMBL5767206

O=C(NCc1ccc2nccc(OCc3ccccc3)c2c1)c1ccc(O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.51
▸ MAPK1 P28482 2/20 0.51
▸ HTT P42858 1/20 0.51
▸ GFER P55789 1/20 0.51
▸ GAA P10253 2/20 0.50
▸ HPGD P15428 2/20 0.50
▸ HDAC1 Q13547 3/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ SGMS2 Q8NHU3 1/20 0.46
▸ KDM1A O60341 1/20 0.46
▸ MAPT P10636 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ HDAC3 O15379 1/20 0.46
▸ HDAC4 P56524 1/20 0.46
▸ HDAC7 Q8WUI4 1/20 0.46
▸ HDAC2 Q92769 1/20 0.46
▸ HDAC10 Q969S8 1/20 0.46
▸ HDAC11 Q96DB2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6780263 0.83 TRPV1 (0.50) MAPK1HDAC1KDM1AMAPTHDAC6
SCHEMBL5764848 0.79 LMNA (0.57) LMNAMAPK1HTTHPGDHDAC1
SCHEMBL5766652 0.76 SLC22A12 (0.43) HTTHPGDSMN1; SMN2MAPTNPC1
SCHEMBL5768126 0.76 LMNA (0.50) LMNAHPGDSMN1; SMN2KMT2AMAPT
SCHEMBL5823771 0.76 SMN1; SMN2 (0.48) LMNAMAPK1HTTGFERHDAC1
SCHEMBL31072687 0.75 RXRA (0.56) HPGDSMN1; SMN2
SCHEMBL6299464 0.75 RXRA (0.52) HPGD
SCHEMBL13491667 0.73 EGLN1 (0.52) LMNAMAPK1HTTGFERGAA
SCHEMBL1681336 0.73 LMNA (0.57) LMNAMAPK1HTTGFERHPGD
SCHEMBL2924662 0.73 HDAC6 (0.74) LMNAMAPK1HPGDHDAC1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615636-A1 BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS PFIZER INC. (US) 2006-01-18 — — EP claimed
WO-2004089366-A1 BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS PFIZER JAPAN, INC. (JP) 2004-10-21 — — WO claimed
US-20040204409-A1 Bicyclic compounds as NR2B receptor antagonists ANDO KAZUO (JP) 2004-10-14 — — US claimed
EP-1615636-A1 BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS PFIZER INC. (US) 2006-01-18 — — EP disclosed
WO-2004089366-A1 BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS PFIZER JAPAN, INC. (JP) 2004-10-21 — — WO disclosed
US-20040204409-A1 Bicyclic compounds as NR2B receptor antagonists ANDO KAZUO (JP) 2004-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204409-A1 Bicyclic compounds as NR2B receptor antagonists GRIN1, GRIN2B, GRIN2A LMNA 3923/4885MAPK1 1578/4885HTT 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback